40541-50-2

Basic information

• Product Name: 2(3H)-Furanone, 3-cyclohexyldihydro-
• CAS NO: 40541-50-2
• Molecular Formula: C10H16O2
• Molecular Weight: 168.236
• Mol File: 40541-50-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2(3H)-Furanone, 3-cyclohexyldihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Furanone, 3-cyclohexyldihydro-(40541-50-2)
• EPA Substance Registry System: 2(3H)-Furanone, 3-cyclohexyldihydro-(40541-50-2)

Safety Data

• Hazardous Substances Data: 40541-50-2(Hazardous Substances Data)

Upstream product

• 96-48-0 4-butanolide 
• 108-94-1 cyclohexanone 
• 6836-98-2 3-phenyldihydrofuran-2-one 
• 201230-82-2 carbon monoxide 
• 42134-55-4 (E)-3-cyclohexyl-2-propen-1-ol 
• 42134-55-4 (Z)-3-cyclohexyl-2-propene-1-ol 

Downstream Products

• 4272-03-1 2-cyclohexyl-1,4-butanediol 
• 91717-39-4 4-Hydroxy-2-cyclohexyl-buttersaeure 
• 911721-88-5 3-cyclohexyl-pyrrolidin-2-one 
• 956319-23-6 2-cyclohexyl-N-(2,6-dichloro-4-methoxy-benzyl)-4-hydroxy-butyramide 
• 956319-24-7 4-bromo-2-cyclohexyl-N-(2,6-dichloro-4-methoxy-benzyl)-butyramide 
• 956319-25-8 trifluoro-methanesulfonic acid 3,5-dichloro-4-(3-cyclohexyl-2-oxo-pyrrolidin-1-ylmethyl)-phenyl ester 

Relevant articles and documents

Lewis Acid Catalyzed Synthesis of α-Trifluoromethyl Esters and Lactones by Electrophilic Trifluoromethylation

An electrophilic trifluoromethylation of ketene silyl acetals (KSAs) by hypervalent iodine reagents 1 and 2 has been developed. The reaction proceeds under very mild conditions in the presence of a catalytic amount of trimethylsilyl bis(trifluoromethanesulfonyl)imide (up to 2.5 mol %) as a Lewis acid providing a direct access to a variety of secondary, tertiary, and quaternary α-trifluoromethyl esters and lactones in high yield (up to 98%).

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11Beta-HSD type 1 activity. X-17377